Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products

The primary concern with unintended humoral immunogenicity of biological products for manufacturers, regulatory agencies, clinicians and patients is whether antibodies produced by patients receiving the product result in clinical sequelae. However, the assessment of the correlation between immunogenicity and clinical sequelae is entirely dependent on the appropriate detection, measurement and characterization of antibodies against biological therapeutics.

Spotlight

ELSALYS BIOTECH

ELSALYS BIOTECH is a fast-growing biotechnology company that designs and develops “best-in-disease” therapeutic antibodies that target tumors and their immune and/or vascular microenvironment. By restoring the ability of immune cells to recognize and kill tumors (Immune Checkpoint Inhibitors or ICI) or by blocking the mechanisms that promote their growth (targeted antibodies), ELSALYS BIOTECH widens the range of combinations of oncology and ophthalmology in novel strong potential therapeutic targets.

OTHER WHITEPAPERS
news image

Antibodies to Viral Vectors Responding to Demands toSimplify Progress in Bioprocessing

whitePaper | March 16, 2023

Biopharma focuses on streamlining biomanufacturing and supply chain issues to drive uptake of cell and gene therapies.

Read More
news image

Biotech Talent Management

whitePaper | February 2, 2022

While many sectors were dealt a severe blow by the COVID-19pandemic, biotech and medtech saw continued growth andare thus attracting top candidates even for non-scientific roles.

Read More
news image

Use of PS-DVB Columns and Matched Buffers in the Purification and Scale-Up of mRNA Drug Candidates

whitePaper | August 24, 2022

The validity of mRNA as an approved pharmaceutical is now largely accepted, with the historic launch and administration of billions of doses of mRNA Covid vaccines (1).

Read More
news image

A Review of RNA Analysis using the Agilent AutomatedElectrophoresis Portfolio

whitePaper | July 15, 2022

Good-quality RNA is crucial to the success of many downstream applications, including qPCR, microarray analysis, and RNA sequencing. Agilent automated

Read More
news image

The biopharmaceutical industry is leading the way in developing vaccines and treatments for COVID-19

whitePaper | April 8, 2020

The rapid spread of the novel coronavirus across the globe is a major public health threat for all, with profound health, social and economic impacts around the world. As a science-driven industry that aims to address some of the world’s biggest healthcare challenges, the research-based biopharmaceutical industry is uniquely positioned to respond rapidly to COVID-19. It has deep scientific knowledge gained from decades of experience working on developing solutions for combatting a range of infectious diseases such as MERS, SARS, Ebola and influenza.

Read More
news image

Using Clinical Breakpoints to Improve Antimicrobial Resistance Detection

whitePaper | December 13, 2022

Define the ongoing pandemic of antimicrobial resistance. Discuss how we can address the ongoing pandemicin the Clinical Microbiology Laboratory

Read More

Spotlight

ELSALYS BIOTECH

ELSALYS BIOTECH is a fast-growing biotechnology company that designs and develops “best-in-disease” therapeutic antibodies that target tumors and their immune and/or vascular microenvironment. By restoring the ability of immune cells to recognize and kill tumors (Immune Checkpoint Inhibitors or ICI) or by blocking the mechanisms that promote their growth (targeted antibodies), ELSALYS BIOTECH widens the range of combinations of oncology and ophthalmology in novel strong potential therapeutic targets.

Events